12-Sep-2019: The global acute
repetitive seizures market size is expected to reach USD
3.19 billion by 2025, according to a new report by Grand View Research, Inc.
The report also states that the market will expand at a strong CAGR of 47.8%
during the forecast period. The rise in the number of initiatives to increase the
awareness about epilepsy is the major factor driving the market.
The market is
currently led by generic drugs which mainly include oral benzodiazepines
(diazepam and lorazepam). Rectal diazepam is the only approved drug for use in
U.S. and buccal midazolam in the European Union. Other drugs, such as diazepam
(oral and intramuscular), midazolam (buccal, intranasal, intramuscular),
lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off
label. The market is expected to be consolidated with a few major companies and
high market share.
Furthermore, in an
attempt to curb healthcare expenditure, governments are making continuous
efforts to reduce hospital stays and on-site treatment costs via outpatient
care models, such as clinic and home healthcare. Emerging economies like India
and China, are increasingly implementing such healthcare reform, which is
expected to propel the growth of acute repetitive seizures market.
There are several
routes of drug administration; out of which, nasal route is the most preferred
over others, such as buccal, rectal, and parenteral. The buccal route is
preferred by caregivers and parents for children suffering from pediatric
seizures since medication can be administered even outside the hospital.
In
depth research report on Acute Repetitive Seizures Market
Further key findings from the study suggest:
·
Global acute repetitive seizures market size was estimated at
USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the
forecast period
·
Diastat rectal gel was the dominant product segment in 2017
due to efficacy of the route of administration and affordability of the product
·
USL-261 is expected to witness a lucrative CAGR over the
forecast period. USL-21 has an edge over the other drugs owing to its superior
clinical profile and positive phase III results
·
North America held the largest share in 2017 due to factors,
such as growing initiatives for raising awareness about epilepsy and seizures
·
Germany is anticipated to witness lucrative growth over the
next decade owing to technological advancements in scientific, clinical, and
medical fields
·
Some of the key companies in the market are UCB S.A.;
Neurelis, Inc.; and Alexza Pharmaceuticals, Inc. These companies are likely to
dominate the market and gain maximum share over the forecast period
Grand View Research
has segmented the global acute repetitive seizures market on the basis of
product and region:
Acute Repetitive Seizures Product Outlook (Revenue, USD
Million, 2013 - 2025)
·
USL-261
·
Neurelis-1
·
AZ-002
·
Diastat Rectal Gel
·
Others
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is the
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment